Despite its re-known pharmacological beneficial effects in condition of ponderal excess both in mice and humans, it has been previously proposed that murine obesity may represent a state of FGF21-resistance [40], although this hypothesis is challenging to translate to humans given the difficulties in the evaluation of FGF21-resistance itself [41]. The gene discussed is FGF21; the disease is obesity due to melanocortin 4 receptor deficiency.